Neurohormone concentrations at baseline and during follow up in the CRT and control groups
| Baseline | 1 month | 12 months | 24 months | |||||
|---|---|---|---|---|---|---|---|---|
| Control (n = 59) | CRT (n = 65) | Control (n = 58) | CRT (n = 65) | Control (n = 53) | CRT (n = 62) | Control (n = 49) | CRT (n = 58) | |
| Data are mean (SD). | ||||||||
| *p<0.05. | ||||||||
| ADH, antidiuretic hormone; NT-proANP, N-terminal fragment of pro-atrial natriuretic peptide; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide. | ||||||||
| Noradrenaline (nmol/l) | 3.34 (1.44) | 3.45 (1.31) | 3.27 (1.29) | 2.56 (1.05)* | 3.56 (1.36) | 2.48 (1.20)* | 3.38 (1.42) | 3.16 (1.27) |
| NT-proANP (pmol/l) | 1672 (922) | 1786 (1003) | 1793 (954) | 1505 (879) | 1544 (1009) | 1698 (975) | 1707 (977) | 1755 (913) |
| NT-proBNP (pmol/l) | 1551 (917) | 1502 (732) | 1492 (869) | 1178 (651)* | 1632 (942) | 1294 (711)* | 1734 (878) | 1561 (667) |
| ADH (pmol/l) | 9.5 (5.0) | 6.9 (3.8) | 7.7 (4.1) | 6.7 (2.9) | 8.78 (3.1) | 9.1 (4.1) | 8.4 (3.7) | 8.4 (4.9) |
| Aldosterone (nmol/l) | 0.30 (0.19) | 0.25 (0.18) | 0.24 (0.15) | 0.21 (0.14) | 0.27 (0.18) | 0.30 (0.19) | 0.26 (0.17) | 0.28 (0.16) |
| Endothelin (pg/ml) | 1.6 (0.9) | 1.7 (0.8) | 1.5 (1.0) | 1.6 (1.1) | 1.8 (1.3) | 1.9 (1.5) | 1.9 (1.2) | 1.6 (0.9) |